Companies /Healthcare

Absci Corp

NASDAQ: ABSI Biotechnology
$8.16
▼ $0.02 (−0.24%) today
Markets closed · 11:53pm ET

ABSI at a Glance

Valuation
Market cap
$1.4B
Profitability
Revenue (TTM)
$1.5M
EPS (TTM)
$-0.79
Price
52-week range
$2 – $13
Street target
$15.09

Headquartered in Vancouver, WA Fiscal year ends December NASDAQ: ABSI absci.com

About Absci

Absci Corporation is a clinical-stage biopharmaceutical company that designs antibody-based therapeutics using generative AI.

Its Integrated Drug Creation platform pairs proprietary AI models with a synthetic biology wet-lab data engine in six-week lab-in-the-loop cycles. The models include the Origin-1 de novo design pipeline (AbsciDiff, AbsciGen, AbsciBind) and AI lead optimization. The platform designs and validates biologics against challenging targets, including epitopes with no known binders.

The company's wholly-owned pipeline centers on prolactin receptor (PRLR) antagonism:
- **ABS-201 in pattern hair loss:** in a Phase 1/2a HEADLINE trial in Australia.
- **ABS-201 in endometriosis:** a planned Phase 2 STORYLINE trial expected to start in mid-2027.
- **ABS-202:** preclinical, for an undisclosed immunology and inflammation indication.
- **ABS-101:** an anti-TL1a candidate for IBD offered for partnering.

Absci also earns partner program revenue from 25+ drug creation collaborations with pharmaceutical, biotech, tech and academic partners. It has begun building commercial infrastructure, including appointing a Chief Commercial Officer.

Operations include AI research labs in New York City and Serbia, a roughly 77,000-square-foot wet and dry lab facility, and an Innovation Center in Switzerland. Updated

Latest Activity

ABSIAbsci
Q3 2026
EPS
-$0.19
est -$0.20+3.9%
Revenue
$304K
est $582K-$278K

Revenue barely registers for a $1.7 billion market cap, and it does not matter: the whole stock rides on 13-week interim hair-loss data from the HEADLINE trial of ABS-201 due in December, with full 26-week results early next year. Cash of $173.7 million funds operations into the second half of 2028, so the December readout sets the next move.

Quarterly EPS — reported vs estimate
ABSIAbsci Corporation
Reports Thu Nov 12Before openConfirmed

Absci reports before the open with no beat streak intact, having landed on the right side of estimates just twice in the last four quarters. Consensus sits at a loss of $0.20 per share, so the AI drug-discovery story turns on pipeline and partnership commentary.

    ABSI Coverage

    Frequently Asked Questions

    What does Absci do?

    Absci Corporation is a clinical-stage biopharmaceutical company that designs antibody-based therapeutics using generative AI. Its Integrated Drug Creation platform pairs proprietary AI models with a synthetic biology wet-lab data engine in six-week lab-in-the-loop cycles.

    What is the ABSI stock price target?

    The Wall Street consensus 12-month price target for ABSI is $15.09.